IP Library Granted Patent US 11,519,019
Granted Patent B2
US 11,519,019 · App. 16/450,918 · Granted Dec 6, 2022

Methods and systems for analyzing nucleic acid molecules

Inventors: Andrew Kennedy (San Diego, CA); Stefanie Ann Ward Mortimer (Morgan Hill, CA); Helmy Eltoukhy (Atherton, CA); AmirAli Talasaz (Menlo Park, CA)
Assignee: Guardant Health, Inc.
C12Q1/6806C12N15/1065C12Q1/6874C12Q1/6886C12Q2600/154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,519,019
App. No.
16/450,918
Granted
Dec 6, 2022
Kind
B2
Abstract

The disclosure provides methods for processing nucleic acid populations containing different forms (e.g., RNA and DNA, single-stranded or double-stranded) and/or extents of modification (e.g., cytosine methylation, association with proteins). These methods accommodate multiple forms and/or modifications of nucleic acid in a sample, such that sequence information can be obtained for multiple forms. The methods also preserve the identity of multiple forms or modified states through processing and analysis, such that analysis of sequence can be combined with epigenetic analysis.

Claims (25)

1. A method of analyzing a cell-free DNA population comprising nucleic acids with different extents of modification, comprising:

contacting the cell-free DNA population with an agent that preferentially binds to nucleic acids bearing the modification, wherein the modification is a post-replication modification to a nucleotide, and wherein the cell-free DNA population is purified from a plasma sample;

separating a first pool of nucleic acids bound to the agent from a second pool of nucleic acids unbound to the agent, wherein the nucleic acids of the first pool are overrepresented for the modification, and the nucleic acids of the second pool are underrepresented for the modification;

linking the nucleic acids in the first pool and/or second pool to one or more nucleic acid tags that distinguish the nucleic acids in the first pool and the second pool to produce a population of tagged nucleic acids;

amplifying the tagged nucleic acids to produce amplified nucleic acids; and

assaying sequence data of the amplified nucleic acids; wherein the assaying comprises:

obtaining sequence data for decoding the tags to reveal whether the nucleic acids for which sequence data has been assayed were amplified from cell-free DNA in the first or the second pool.

2. The method of claim 1 , comprising the step of decoding the tags to reveal whether the nucleic acids for which sequence data has been assayed were amplified from cell-free DNA in the first or the second pool.

3. The method of claim 1 , wherein the post-replication modification is 5-methyl-cytosine, and the extent of binding of the agent to nucleic acids increases with the extent of 5-methyl-cytosines in the nucleic acid.

4. The method of claim 1 , wherein the post-replication modification is 5-hydroxymethyl-cytosine, and the extent of binding of the agent to nucleic acid increases with the extent of 5-hydroxymethyl-cytosine in the nucleic acid.

5. The method of claim 1 , wherein the post-replication modification is 5-formyl-cytosine or 5-carboxyl-cytosine and the extent of binding of the agent increases with the extent of 5-formyl-cytosine or 5-carboxyl-cytosine in the nucleic acid.

6. The method of claim 1 , further comprising washing nucleic acids bound to the agent and collecting the wash as a third pool including nucleic acids with the post replication modification at an intermediate extent relative to the first and second pools.

7. The method of claim 1 , comprising, before assaying, pooling tagged nucleic acids from the first and second pools.

8. The method of claim 1 , wherein the agent is 5-methyl-binding domain magnetic beads.

9. The method of claim 1 , wherein the cell-free DNA population is from a bodily fluid sample.

10. The method of claim 9 , wherein the bodily fluid sample is blood, serum, or plasma.

11. The method of claim 9 , wherein the bodily fluid sample is from a subject suspected of having a cancer.

12. The method of claim 1 , wherein the sequence data indicates presence of a somatic or germline variant.

13. The method of claim 1 , wherein the sequence data indicates presence of a copy number variation.

14. The method of claim 1 , wherein the sequence data indicates presence of a single nucleotide variation (SNV), indel or gene fusion.

15. The method of claim 1 , further comprises, enriching the amplified nucleic acids for a plurality of genomic regions.

16. The method of claim 15 , wherein the enrichment is performed by hybridization of amplified nucleic acids to RNA or DNA probes.

17. The method of claim 15 , wherein the first pool and second pool are enriched for at least one same genomic region in the plurality of genomic regions.

18. The method of claim 1 , wherein the assaying comprises determining a quantitative measure obtained from a plurality of sequencing reads in the first and/or second pool.

19. The method of claim 1 , further comprises, attaching one or more sample tags to the amplified nucleic acids.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2020
From: KENNEDY, ANDREW; MORTIMER, STEFANIE ANN WARD; ELTOUKHY, HELMY; TALASAZ, AMIRALI; ABDUEVA, DIANA; SCHULTZ, MATTHEW
To: GUARDANT HEALTH, INC.
Reel/Frame 052451/0820 →
Continuity (5)
Continuation PCTUS2017068329 · Dec 22, 2017
Provisional Application 62438240 · Dec 22, 2016
Provisional Application 62512936 · May 31, 2017
Provisional Application 62550540 · Aug 25, 2017
Related Publication 20190390253A1 · Dec 26, 2019
Cited By (2)
US 12,509,733 US 12,630,866